Literature DB >> 15638100

The effects of 2% ibopamine eye drops on the intraocular pressure and pupil motility of patients with open-angle glaucoma.

I Giuffrè1, L Taverniti, S Di Staso.   

Abstract

PURPOSE: Ibopamine is a prodrug of N-methyldopamine that has a non-cycloplegic mydriatic action due to its alpha-adrenergic properties and is able to induce, when topically given, a transient increase of intraocular pressure (IOP) in eyes with hydrodynamic disorders.
METHODS: This is a randomized, crossover, open-labeled, two- center study. Forty patients (20 open-angle glaucoma patients and 20 healthy subjects) were treated with ibopamine 2% eye drops and phenylephrine 10% eye drops.
RESULTS: Ibopamine induced a significant increase in IOP only in glaucomatous eyes (p<0.001) without a significant hypertensive effect in normal eyes. Ibopamine and phenylephrine showed a similar mydriatic activity but ibopamine was able to induce an hypertensive effect only in glaucomatous eyes.
CONCLUSIONS: The results confirm the use of ibopamine as provocative test in detection of hydrodynamic disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15638100     DOI: 10.1177/112067210401400610

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  3 in total

1.  Intraocular silicone implant to treat chronic ocular hypotony: an in vivo trial.

Authors:  Wesal Bayoudh; Dörthe Carstesen; Peter Walter; Andreas W A Weinberger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-03       Impact factor: 3.117

2.  Evaluating the efficacy of short duration Mitomycin C in safe surgery system trabeculectomy combined with cataract surgery.

Authors:  Rekha Khandelwal; Madhavi Bijlani; Dhananjay Raje; Anand Rathi
Journal:  Clin Ophthalmol       Date:  2019-05-22

3.  Frequency Doubling Technology vs Standard Automated Perimetry in Ocular Hypertensive Patients.

Authors:  Italo Giuffrè
Journal:  Open Ophthalmol J       Date:  2009-03-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.